Lucinactant delivered via investigational delivery device
03-CL-1202
Phase 2 small_molecule completed
Quick answer
Lucinactant delivered via investigational delivery device for Respiratory Distress Syndrome is a Phase 2 program (small_molecule) at WINDTREE THERAPEUTICS INC /DE/ with 1 ClinicalTrials.gov record(s).
Program details
- Company
- WINDTREE THERAPEUTICS INC /DE/
- Indication
- Respiratory Distress Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed